两家公司共同押注,自免新王牌即将亮剑?

Ofweek维科网
02 Jul

CD38抗体自免肾病预期升温。6月30日,Biogen发布公告,宣布felzartamab(中文通用名:菲泽妥单抗)治疗原发性膜性肾病(PMN)的全球三期研究PROMINENT(NCT06962800)已完成首例患者给药。这意味着,继AMR的TRANSCEND研究(NCT06685757)和IgAN的PREVAIL研究(NCT06935357)之后,这款CD38抗体在自免肾病领域的三项全球三期...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10